down arrow

Kyverna Therapeutics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US5019761049
USD
7.19
0.19 (2.71%)

Dec 19

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

7.057.40

52 Week

1.7813.64
Valuation
Technical
Day's Volume

CASH

718.03 k

Shareholding (Mar 2025)

FII

10.64%

Held by 58 FIIs

DII

27.29%

Held by 22 DIIs

Promoter

44.66%

How big is Kyverna Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Kyverna Therapeutics, Inc. has a market capitalization of 127.93 million and reported net sales of 0.00 million with a net profit of -145.41 million over the latest four quarters. Shareholder's funds were 266.59 million, and total assets were 306.52 million as of Dec 24.

As of Jun 18, Kyverna Therapeutics, Inc. has a market capitalization of 127.93 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 0.00 million for the latest four quarters, with a net profit of -145.41 million during the same period.<BR><BR>As of Dec 24, the company's shareholder's funds amounted to 266.59 million, and total assets were reported at 306.52 million.

Read More

What does Kyverna Therapeutics, Inc. do?

22-Jun-2025

Kyverna Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $45 million and a market cap of $127.93 million. Key metrics include a P/E ratio of NA, a dividend yield of 0.00%, and a return on equity of -64.92%.

Overview:<BR>Kyverna Therapeutics, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Net Profit: -45 Million (Quarterly Results - Mar 2025) <BR>Market Cap: USD 127.93 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.07 <BR>Return on Equity: -64.92% <BR>Price to Book: 0.57 <BR><BR>Contact Details:<BR>Registrar Address: Not available.

Read More

Is Kyverna Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of August 7, 2025, Kyverna Therapeutics, Inc. shows a mildly bullish trend driven by short-term indicators, despite longer-term underperformance compared to the S&P 500.

As of 7 August 2025, the technical trend for Kyverna Therapeutics, Inc. has changed from mildly bearish to mildly bullish. The weekly MACD is bullish, and the daily moving averages also indicate a bullish stance. However, the monthly MACD and KST are bearish, suggesting some caution. The Bollinger Bands show a bullish signal on the weekly timeframe but are mildly bearish monthly. Dow Theory supports a mildly bullish outlook on both weekly and monthly charts. <BR><BR>In terms of performance, the stock has outperformed the S&P 500 significantly over the past week and month, with returns of 20.72% and 41.53% compared to the S&P's 1.05% and 2.33%, respectively. However, the longer-term returns indicate underperformance, with a 1-year return of -24.09% versus the S&P's 17.14%. Overall, the current technical stance is mildly bullish, driven primarily by short-term indicators.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 169 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.13

stock-summary
Return on Equity

-86.07%

stock-summary
Price to Book

0.91

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-42 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
23.97%
0%
23.97%
6 Months
147.08%
0%
147.08%
1 Year
85.79%
0%
85.79%
2 Years
-43.21%
0%
-43.21%
3 Years
-43.21%
0%
-43.21%
4 Years
-43.21%
0%
-43.21%
5 Years
-43.21%
0%
-43.21%

Kyverna Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-100.00%
EBIT Growth (5y)
-250.54%
EBIT to Interest (avg)
-120.49
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.07
Sales to Capital Employed (avg)
4.73
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.65
EV to EBIT
0.58
EV to EBITDA
0.58
EV to Capital Employed
6.15
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
1067.18%
ROE (Latest)
-64.92%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 29 Schemes (17.4%)

Foreign Institutions

Held by 58 Foreign Institutions (10.64%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -46.18% vs -119.85% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-43.90",
          "val2": "-32.90",
          "chgp": "-33.43%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-42.10",
          "val2": "-28.80",
          "chgp": "-46.18%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -111.09% vs -109.00% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-140.50",
          "val2": "-60.70",
          "chgp": "-131.47%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.20",
          "chgp": "-50.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-127.50",
          "val2": "-60.40",
          "chgp": "-111.09%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-43.90
-32.90
-33.43%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-42.10
-28.80
-46.18%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -46.18% vs -119.85% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-140.50
-60.70
-131.47%
Interest
0.10
0.20
-50.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-127.50
-60.40
-111.09%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -111.09% vs -109.00% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Kyverna Therapeutics, Inc. stock-summary
stock-summary
Kyverna Therapeutics, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."